Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07173634

Speaking Valve Trial vs. Capping Trial for Tracheostomy Decannulation in Prolonged Disorders of Consciousness

To assess whether the speaking valve trial, when employed as an indicator for extubation during the removal of tracheostomy tubes in patients with chronic consciousness disorder, provides superior benefits and heightened sensitivity relative to the conventional capping trial, thereby enhancing the overall extubation process.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Rehabilitation Hospital, Capital Medical University, Beijing,China

Beijing, Beijing Municipality, 100043, China

About this study

Patients with chronic consciousness disorder who require long-term mechanical ventilation and airway protection commonly undergo tracheostomy. However, tracheostomy tubes can cause inflammation, stenosis, excessive coughing, and swallowing dysfunction. Removing the tracheostomy tube, or extubation, can prevent long-term complications such as tracheal stenosis, tracheomalacia, vocal cord injury, and accidental extubation. Additionally, it enhances patient comfort, appearance, swallowing function, communication ability, and social integration. Therefore, for clinically stable patients with chronic consciousness disorder who can breathe spontaneously, have effective cough reflexes, and are capable of protecting their airways, early tube removal is advisable.In current extubation protocols, the capping trial is predominantly used to assess whether patients can tolerate tracheostomy tube removal. There have also been reports of studies using speaking valves as an alternative to the capping trial, but no direct comparison has been made between the two methods. Patients who can tolerate capping for 24 hours are generally considered suitable for tracheostomy tube removal. A speaking valve is a one-way valve placed at the end of the tracheostomy tube that directs airflow to the upper airway when the cuff is deflated. Studies have found that patients undergoing speaking valve training benefit in terms of vital signs, airway secretions, sense of smell, weaning from mechanical ventilation, post-tracheostomy extubation, hospital stay duration, and quality of life. However, it remains unclear whether this method can improve the success rate of extubation assessment in patients with chronic consciousness disorder. This study compares speaking valve training and the traditional capping trial in post-tracheostomy patients with chronic consciousness disorder, evaluating differences in extubation tolerance, extubation success rate, time to extubation, hospital stay duration, and improvement in consciousness levels.

Parazacco spilurus subsp. spilurus

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (18-80 years) with tracheostomy
  • Prolonged DoC (>28 days) confirmed by CRS-R score >0
  • Ventilator-free >48h
  • PaCO₂ <60 mmHg
  • PCF ≥100 L/min
  • No sepsis/organ failure
  • Controlled pulmonary infection
  • Written informed consent by legal representative

Exclusion criteria

  • Intolerance to cuff deflation:
  • SpO₂ <93% on O₂ supplementation OR Respiratory rate >20/min for >5min
  • Severe tracheal stenosis (>50% lumen occlusion on CT)
  • Death within 2 weeks post-enrollment
  • Participation in conflicting interventional trial

Treatment and study plan

Speaking Valve Trial

Other

The speaking valve group ascertains a patient's eligibility for decannulation following the results of the speaking valve test. A patient who can endure a 4-hour trial with a speaking valve, maintaining a pulse oxygen saturation (SpO₂) of at least 95%, a breathing rate (RR) below 20 per minute, and exhibiting no signs of distress throughout the trial, qualifies for decannulation.

Capping Trial

Other

The capping valve group determines a patient's eligibility for decannulation based on the results of the capping test. A patient who can tolerate 48 hours of capping with a pulse oxygen saturation (SpO₂) of ≥95%, a breathing rate (RR) of <20/min, and no signs of distress during the 48-hour trial, is eligible for decannulation.

Primary outcomes

  1. Decannulation rate

    Time frame: At decannulation

    Proportion passing full protocol

  2. Decannulation success rate

    Time frame: At 48 h post decannulation

    (Decannulation - Decannulation failure ) / Decannulation

Secondary outcomes

  1. Time to decannulation

    Time frame: 1year

    Days from randomization to successful tube removal

  2. Hospital stay duration

    Time frame: Up to 6 months

    Days from randomization to discharge without tracheostomy care

  3. CRS-R change rate

    Time frame: 3 months

    (Post-decannulation score - Baseline)/Baseline

  4. Airway safety score1

    Time frame: 48h post-decannulation

    Pulse oxygen saturation (SpO₂) fluctuation, minimum value0%, maximum value 100%, the larger the value, the better the result

  5. Airway safety score 2

    Time frame: 48h post-decannulation

    Blood carbon dioxide partial pressure (pCO₂) , normal range 35-45mmHg. Within the normal range it is good, the greater the deviation from the normal range, the worse the result the larger the value, the better the result.

Sponsors and collaborators

Lead sponsor

Hongying Jiang, MD

Other

Collaborators

  • Beijing Fengtai Rehabilitation Hospital
  • Beijing Rehabilitation Hospital of Capital Medical University
  • Beijing Tiantan Hospital
  • Hunan Provincial Rehabilitation Hospital

Registry information

Official study title

Comparison of Speaking Valve Trial Versus Capping Trial in the Decannulation Process for Patients With Prolonged Disorders of Consciousness: A Randomized Controlled Study

Acronym: SPEAK-CAP

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 15, 2025
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.